Menu Search
Equities

Kissei Pharmaceutical Co Ltd

4547:TYO

Kissei Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)3,600.00
  • Today's Change-55.00 / -1.50%
  • Shares traded167.70k
  • 1 Year change+16.69%
  • Beta0.5006
Data delayed at least 20 minutes, as of Nov 25 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy0
Outperform1
Hold3
Sell0
Strong Sell0

Share price forecast in JPY

The 4 analysts offering 12 month price targets for Kissei Pharmaceutical Co Ltd have a median target of 3,725.00, with a high estimate of 4,400.00 and a low estimate of 3,440.00. The median estimate represents a 3.47% increase from the last price of 3,600.00.
High22.2%4,400.00
Med3.5%3,725.00
Low-4.4%3,440.00

Dividends in JPY

In 2024, Kissei Pharmaceutical Co Ltd reported a dividend of 82.00 JPY, which represents a 2.50% increase over last year. The 2 analysts covering the company expect dividends of 90.00 JPY for the upcoming fiscal year, an increase of 9.76%.
Div growth (TTM)2.50%
More ▼

Earnings history & estimates in JPY

On Nov 05, 2024, Kissei Pharmaceutical Co Ltd reported 2nd quarter 2025 earnings of 25.86 per share.
The next earnings announcement is expected on May 05, 2025.
Average growth rate-1.59%
Kissei Pharmaceutical Co Ltd reported annual 2024 earnings of 246.61 per share on May 07, 2024.
Average growth rate+56.17%
More ▼

Revenue history & estimates in JPY

Kissei Pharmaceutical Co., Ltd. had 2nd quarter 2025 revenues of 21.30m. This was 10.30% above the prior year's 2nd quarter results.
Average growth rate+5.79%
Kissei Pharmaceutical Co., Ltd. had revenues for the full year 2024 of 75.58m. This was 11.98% above the prior year's results.
Average growth rate+4.77%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.